ASH 2020 | The SADAL study: selinexor for R/R DLBCL

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, discusses the Phase 2b SADAL study (NCT02227251) of selinexor, a first-in class selective inhibitor of nuclear export that blocks XPO1, forcing the re-activation of tumor suppressor proteins such as p53, p73, FOXO, IkB and Rb. The safety and efficacy of selinexor was studied in a group of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) that had undergone several lines of treatment, where 17.3% and 11% of patients under 65 years old and over 65 years old respectively achieved a complete response (CR). Progression-free survival (PFS) was 3.6 and 2.3 months respectively. Adverse events associated with selinexor were manageable and include thrombocytopenia, nausea and fatigue. The next steps will be exploring the drug with other combinations and moving the drug forward to earlier lines of treatment. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.